SEARCH

SEARCH BY CITATION

References

  • 1
    Crooke ST (ed.). Antisense Drug Technology Principle, Strategies, and Applications, Second edn. Baco Raton: CRC Press, 2007.
  • 2
    Crooke ST, Vickers T, Lima W, Wu H. Mechanisms of antisense drug action. In: Antisense Drug Technology Principle, Strategies, and Applications, Second edn. ed. Crooke ST . Baco Raton: CRC Press, 2007; 346.
  • 3
    Liang X, Vickers T, Crooke ST. Antisense-mediated reduction of eukaryotic non-coding RNAs. In: Nucleic Acids Sequences to Molecular Medicine, eds Erdmann WA , Barciszewski J . New York: Springer, 2012; 191214.
  • 4
    Lima W, Wu H, Crooke ST. The RNase H mechanism. Mechanisms of antisense drug action. In: Antisense Drug Technology Principle, Strategies, and Applications, Second edn. ed. Crooke ST . Baco Raton: CRC Press, 2007; 4774.
  • 5
    Swayze EE, Bhat B. The medicinal chemistry of oligonucleotides. Mechanisms of antisense drug action. In: Antisense Drug Technology Principle, Strategies, and Applications, Second edn. ed. Crooke ST . Baco Raton: CRC Press, 2007; 143182.
  • 6
    Bennett CF. Pharmacological properties of 2′-O-methoxyethyl-modified oligonucleotides. Mechanisms of antisense drug action. In: Antisense Drug Technology Principle, Strategies, and Applications, Second edn. ed. Crooke ST . Baco Raton: CRC Press, 2007; 273303.
  • 7
    Levin AA, Yu RZ, Geary RS. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. Mechanisms of antisense drug action. In: Antisense Drug Technology Principle, Strategies, and Applications, Second edn. ed. Crooke ST . Baco Raton: CRC Press, 2007; 183215.
  • 8
    Hardee GE, Tillman LG, Geary RS. Routes and formulations for delivery of antisense oligonucleotides. Mechanisms of antisense drug action. In: Antisense Drug Technology Principle, Strategies, and Applications, Second edn. ed. Crooke ST . Baco Raton: CRC Press, 2007; 217236.
  • 9
    Geary RS, Yu RZ, Siwkowski A, Levin AA. Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2′-O-(2-methoxyethyl)-modified oligonucleotides in animals and man. Mechanisms of antisense drug action. In: Antisense Drug Technology Principle, Strategies, and Applications, Second edn. ed. Crooke ST . Baco Raton: CRC Press, 2007; 305326.
  • 10
    Davidson NO, Shelness GS. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20: 169193.
  • 11
    Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002; 162: 227244.
  • 12
    Das HK, Leff T, Breslow JL. Cell type-specific expression of the human apoB gene is controlled by two cis-acting regulatory regions. J Biol Chem 1988; 263: 1145211458.
  • 13
    Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J 2012; 33: 14511458.
  • 14
    Ricotta DN, Frishman W. Mipomersen: a safe and effective anti-sense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev 2012; 20: 9095.
  • 15
    Haddley K. Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia. Drugs Today (Barc) 2011; 47: 891901.
  • 16
    Crooke RM, Graham MJ. Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia. Clin Lipidol 2011; 6: 675692.
  • 17
    Bell DA. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs 2011; 20: 265272.
  • 18
    Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJ, Trip MD, Stroes ES. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010; 51: 10571062.
  • 19
    Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipemersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomized, double-blind, placebo controlled trial. Lancet 2010; 375: 9981006.
  • 20
    Duell PB, Santos RD, East C, Guyton JR, Moriarty P, Donovan JM, Mittleman RS. Long-term safety and efficacy of mipomersen in patients with familial hypercholesterolemia uncontrolled by maximally tolerated lipid lowering therapy. J Clin Lipidol 2012; 6: 291.
  • 21
    Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005; 46: 872874.
  • 22
    Crooke RM, Baker BF, Wedel MK. Cardiovascular therapeutic applications. In: Antisense Drug Technology Principle, Strategies, and Applications, Second edn. ed. Crooke ST . Baco Raton: CRC Press, 2007; 601639.
  • 23
    Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 17291735.
  • 24
    Adkim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, Flaim JD, Su J, Stein EA, Kastelein JJ. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010; 105: 113131.
  • 25
    Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, Baker BF, Wedel MK, Kastelein JJ. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2011; 55: 16111618.
  • 26
    Akdim F, Tribble DL, Flaim JD, Yu R, Su J, Geary RS, Baker BF, Fuhr R, Wedel MK, Kastelein JJ. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-moderate hyperlipidaemia. Eur Heart J 2011; 32: 26502659.
  • 27
    Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense Oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007; 35: 460463.
  • 28
    Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, Levin AA, Geary RS. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009; 77: 910919.
  • 29
    Yu RZ, Geary RS, Flaim JD, Riley GC, Tribble DL, van Vliet AA, Wedel MK. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009; 48: 3950.
  • 30
    Visser Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, Nederveen AJ, Verheij J, Trip MD, Basart DC, Kastelein JJ, Stroes ES. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012; 33: 11421149.